Answers are grounded in this paper and cite their sources.
Our study highlighted the advantage of ctDNA analysis for monitoring tumor evolution. TP53 mutations promoted genetic evolution and accelerated occurrence of resistance. We also unveiled ALK-dependent resistance mechanisms, mainly by G1269A, G1202R, and E1210K mutations, and ALK-independent resistance mechanisms to ensartinib.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: